Kypha Information

Kypha discovers, develops and commercializes innovative in-vitro diagnostic biomarker tests within the inflammation and autoimmune space. These tests have application across a wide range of indications that include: lupus, stroke, traumatic brain injury, preeclampsia, infection, nephrology/kidney disease and transplant rejection. Potential implications include detecting the onset of adverse events earlier and optimizing treatment sooner, predicting outcomes more accurately, and managing disease and patient more effectively. Based on the ability to measure complement activation within the body, the company has developed a point of care platform called “COMP ACT” that delivers real time results to the physicians. Kypha has developed an extensive clinical collaborator network to support the clinical trials as well as the identification of new biomarkers across multiple indications.